

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of April 2023**

**Commission File Number: 001-41421**

---

**Alvotech**

**(Translation of registrant's name into English)**

---

**9, Rue de Bitbourg,  
L-1273 Luxembourg,  
Grand Duchy of Luxembourg**  
**(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F       Form 40-F

---

---

**Announcement**

Alvotech has been informed by the U.S. Food and Drug Administration (FDA) that the responses provided to the FDA Form 483 on April 3, 2023, following the conclusion of the reinspection of the company's Reykjavik facility on March 17, 2023, are currently under review.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: April 17, 2023

**ALVOTECH**

By: /s/ Tanya Zharov  
Name: Tanya Zharov  
Title: General Counsel